NCT04528329.

Study name	Anosmia and/or ageusia and early corticosteroid use
Methods	Randomised controlled trial
Participants	Adult participants with mild to moderate severity COVID‐19 Inclusion Diagnosis of COVID‐19 ≥ 18 years of age Mild to moderate severity Exclusion  Diabetes  Contraindication to dexamethasone  Mental disability  Planned sample size: 300 participants
Interventions	Intervention: "Early dexamethasone use as early as confirmation of inflammation" Comparator: "Late dexamethasone use as soon as deterioration"
Outcomes	Outcomes of interest in the review: Primary outcomes: Recovery of sense of smell Time to recovery from anosmia  (no further details provided) Disease‐related quality of life Not reported Serious adverse effects  Not reported Secondary outcomes: Change in sense of smell Not reported Overall, generic quality of life Not reported Prevalence of parosmia Not reported Other adverse effects (including nosebleeds/bloody discharge) Not reported Other outcomes reported by the study: None reported
Starting date	30 August 2020
Contact information	Emad R Issak Email: dr.emad.r.h.issak@gmail.com
Notes	Estimated study completion date: 15 December 2020  Trial registered in Egypt  Uncertainty over future inclusion in the review: It is not clear from the description provided whether participants will all have olfactory dysfunction at baseline and, if so, whether they will have ≥ 4 weeks of olfactory dysfunction. We are awaiting confirmation from the study authors.